Literature DB >> 16754901

Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism.

Jacques Turgeon1, Chantal Pharand, Véronique Michaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16754901      PMCID： PMC1471829          DOI： 10.1503/cmaj.060502

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  30 in total

1.  Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

Authors:  Kyung-Sang Yu; Joo-Youn Cho; In-Jin Jang; Kyoung-Seop Hong; Jae-Yong Chung; Jung-Ryul Kim; Hyeong-Seok Lim; Dal-Seok Oh; So-Young Yi; Kwang-Hyeon Liu; Jae-Gook Shin; Sang-Goo Shin
Journal:  Clin Pharmacol Ther       Date:  2004-08       Impact factor: 6.875

2.  Pharmacokinetics of clopidogrel after administration of a high loading dose.

Authors:  Dirk Taubert; Adnan Kastrati; Steffi Harlfinger; Olga Gorchakova; Andreas Lazar; Nicolas von Beckerath; Albert Schömig; Edgar Schömig
Journal:  Thromb Haemost       Date:  2004-08       Impact factor: 5.249

3.  Role of itraconazole metabolites in CYP3A4 inhibition.

Authors:  Nina Isoherranen; Kent L Kunze; Kyle E Allen; Wendel L Nelson; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2004-07-08       Impact factor: 3.922

4.  Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

Authors:  Pierre Fontana; Annabelle Dupont; Sophie Gandrille; Christilla Bachelot-Loza; Jean-Luc Reny; Martine Aiach; Pascale Gaussem
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

5.  Effects of statins on platelet inhibition by a high loading dose of clopidogrel.

Authors:  Iris Müller; Felicitas Besta; Christian Schulz; Zhongyan Li; Steffen Massberg; Meinrad Gawaz
Journal:  Circulation       Date:  2003-10-20       Impact factor: 29.690

6.  Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.

Authors:  Victor L Serebruany; Mark G Midei; Alex I Malinin; Benjamin R Oshrine; David R Lowry; David C Sane; Jean-François Tanguay; Steven R Steinhubl; Peter B Berger; Christopher M O'Connor; Charles H Hennekens
Journal:  Arch Intern Med       Date:  2004-10-11

7.  Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.

Authors:  Su-Jun Lee; Khawja A Usmani; Brian Chanas; Burhan Ghanayem; Tina Xi; Ernest Hodgson; Harvey W Mohrenweiser; Joyce A Goldstein
Journal:  Pharmacogenetics       Date:  2003-08

8.  Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.

Authors:  Wei C Lau; Paul A Gurbel; Paul B Watkins; Charlene J Neer; Amy S Hopp; David G M Carville; Kirk E Guyer; Alan R Tait; Eric R Bates
Journal:  Circulation       Date:  2004-01-05       Impact factor: 29.690

9.  Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

Authors:  John V Mitsios; Athanasios I Papathanasiou; Foteini I Rodis; Moses Elisaf; John A Goudevenos; Alexandros D Tselepis
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

10.  Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study.

Authors:  Horst Neubauer; Bülent Günesdogan; Christoph Hanefeld; Martin Spiecker; Andreas Mügge
Journal:  Eur Heart J       Date:  2003-10       Impact factor: 29.983
View more
  1 in total

Review 1.  Platelet activation, and antiplatelet targets and agents: current and novel strategies.

Authors:  Yao-Zu Xiang; Ye Xia; Xiu-Mei Gao; Hong-Cai Shang; Li-Yuan Kang; Bo-Li Zhang
Journal:  Drugs       Date:  2008       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.